DEF 14A

Company

Avalo Therapeutics, Inc.

Filed

October 19, 2023

Period of Report

December 5, 2023

Accession Number

0001628280-23-034686

A DEF 14A is a proxy statement sent to shareholders before an annual meeting. It covers executive compensation, board elections, and shareholder votes. Learn more about DEF 14A filings →